SON-1010 for Solid Tumors, Advanced Solid Tumors

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Sarcoma Oncology Center, Santa Monica, CA
Solid Tumors, Advanced Solid Tumors+1 More
SON-1010 - Biological
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This is a Phase 1, first-in-human, open-label, adaptive-design outpatient study to assess the safety, tolerability, and PK/PD of SON-1010 administered to patients with advanced solid tumors.

Eligible Conditions

  • Solid Tumors, Advanced Solid Tumors

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Solid Tumors, Advanced Solid Tumors

Study Objectives

3 Primary · 4 Secondary · Reporting Duration: Through study completion, an average of 1 year

Day 28
Effect of SON-1010 on Serum cytokine levels
Serum and urine concentrations of SON-1010 will be determined at various time points
Day 28
Evaluation of SON-1010 immunogenicity
Year 1
To assess the antitumor activity of SON-1010
To establish the maximum tolerated dose (MTD) of SON-1010
To establish the recommended Phase 2 dose (RP2D) of SON-1010
To evaluate the safety and tolerability of SON-1010

Trial Safety

Safety Progress

1 of 3

Other trials for Solid Tumors, Advanced Solid Tumors

Trial Design

6 Treatment Groups

Dose Level 3
1 of 6
Dose Level 4
1 of 6
Dose Level 1
1 of 6
Dose Level 2
1 of 6
Dose Level 5
1 of 6
RP2D Expansion
1 of 6
Experimental Treatment

36 Total Participants · 6 Treatment Groups

Primary Treatment: SON-1010 · No Placebo Group · Phase 1

Dose Level 3
Biological
Experimental Group · 1 Intervention: SON-1010 · Intervention Types: Biological
Dose Level 4
Biological
Experimental Group · 1 Intervention: SON-1010 · Intervention Types: Biological
Dose Level 1
Biological
Experimental Group · 1 Intervention: SON-1010 · Intervention Types: Biological
Dose Level 2
Biological
Experimental Group · 1 Intervention: SON-1010 · Intervention Types: Biological
Dose Level 5
Biological
Experimental Group · 1 Intervention: SON-1010 · Intervention Types: Biological
RP2D Expansion
Biological
Experimental Group · 1 Intervention: SON-1010 · Intervention Types: Biological

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: through study completion, an average of 1 year
Closest Location: Sarcoma Oncology Center · Santa Monica, CA
Photo of santa monica  1Photo of santa monica  2Photo of santa monica  3
2014First Recorded Clinical Trial
3 TrialsResearching Solid Tumors, Advanced Solid Tumors
47 CompletedClinical Trials

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have a performance status of 0 or 1.
You have a solid epithelial or mesenchymal tumor.
You have no alternative treatment options that are considered by the treating physician to offer reasonable or potentially better benefit, or are not a candidate for standard therapy for your disease due to an underlying physical condition.
You must weigh 50 kg or less to receive SON-1010.
You have a GFR ≥45 mL/min/1.73 m2.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.